We are not a marijuana stock, perhaps that is the "problem". We are a biopharmaceutical stock specializing in cannabis based products. We don't profit from the legalization of MJ. Now if the company would decide to enter that market with the sublingual tablets, that's another story but I don't see that happening yet.
News 
Market Data 
Discover 
AI
